Autologous stem cell therapy - Opexa Therapeutics

Drug Profile

Autologous stem cell therapy - Opexa Therapeutics

Alternative Names: MDIs - Opexa

Latest Information Update: 26 Mar 2014

Price : $50

At a glance

  • Originator Opexa Therapeutics
  • Class Antineoplastics; Cardiovascular therapies; Cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements; Pancreatic beta cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Type 1 diabetes mellitus
  • Discontinued Heart failure

Most Recent Events

  • 26 Mar 2014 Autologous stem cell therapy is still in preclinical trials for Type-1 diabetes mellitus in the USA
  • 26 Mar 2014 Discontinued - Preclinical for Heart failure in USA (Implant)
  • 19 Jul 2010 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top